Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28588436 | 0.87 | KMT2A (0.55) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL3334714 | 0.87 | ALDH1A1 (0.51) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL7804122 | 0.85 | PLA2G4B (0.60) | ALDH1A1GAAKDM4EPLA2G4B | |
| SCHEMBL2768717 | 0.85 | SLC7A5 (0.48) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL334386 | 0.85 | SLC7A5 (0.48) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL2767522 | 0.85 | SLC7A5 (0.48) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL3868045 | 0.84 | SLC7A5 (0.47) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL4591522 | 0.84 | KDM4E (0.52) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL3984588 | 0.84 | SLC7A5 (0.50) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E | |
| SCHEMBL3979830 | 0.84 | SLC7A5 (0.47) | SLC7A5SMN1; SMN2ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | claimed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | claimed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | claimed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | SLC7A5 4025/4885SMN1; SMN2 4033/4885ALDH1A1 2568/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | SLC7A5 4025/4885SMN1; SMN2 4033/4885ALDH1A1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.